Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Change in Accured Expenses (2017 - 2023)

Dianthus Therapeutics has reported Change in Accured Expenses over the past 6 years, most recently at -$1.7 million for Q2 2023.

  • Quarterly results put Change in Accured Expenses at -$1.7 million for Q2 2023, down 169.82% from a year ago — trailing twelve months through Jun 2023 was -$2.6 million (down 709.15% YoY), and the annual figure for FY2022 was $973000.0, up 535.95%.
  • Change in Accured Expenses for Q2 2023 was -$1.7 million at Dianthus Therapeutics, up from -$3.3 million in the prior quarter.
  • Over the last five years, Change in Accured Expenses for DNTH hit a ceiling of $3.7 million in Q4 2019 and a floor of -$3.3 million in Q1 2023.
  • Median Change in Accured Expenses over the past 4 years was -$623000.0 (2022), compared with a mean of -$136818.2.
  • Biggest five-year swings in Change in Accured Expenses: soared 643.89% in 2019 and later tumbled 288.71% in 2023.
  • Dianthus Therapeutics' Change in Accured Expenses stood at $3.7 million in 2019, then crashed by 168.62% to -$2.5 million in 2020, then skyrocketed by 159.64% to $1.5 million in 2022, then crashed by 210.66% to -$1.7 million in 2023.
  • The last three reported values for Change in Accured Expenses were -$1.7 million (Q2 2023), -$3.3 million (Q1 2023), and $1.5 million (Q4 2022) per Business Quant data.